Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
<p><strong>Objectives:</strong> MAXIMISE trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of PsA.</p> <p><strong>Methods:</strong> This phase 3b, double-blind, placebo-controlled, multicentre 52-week trial...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ
2020
|